The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
 

Editor

Share

Personal info

View

Links

Table of contents

About

Terms

 

Terry A. Jacobson

Department of Medicine

Office of Health Promotion and Disease Prevention

Emory University

Atlanta

USA

[email]@emory.edu

Name/email consistency: high

 
 
 
 
 
 
 

Affiliations

  • Department of Medicine, Office of Health Promotion and Disease Prevention, Emory University, Atlanta, USA. 2003 - 2012
  • Department of Medicine, Emory University, Atlanta, GA 30303, USA. 1998 - 2007
  • Department of Medicine, Emory University School of Medicine, Grady Health System, Atlanta, USA. 1999 - 2001

References

  1. A new pure ω-3 eicosapentaenoic acid ethyl ester (AMR101) for the management of hypertriglyceridemia: the MARINE trial. Jacobson, T.A. Expert. Rev. Cardiovasc. Ther (2012) [Pubmed]
  2. Opening a New Lipid "Apo-thecary": Incorporating Apolipoproteins as Potential Risk Factors and Treatment Targets to Reduce Cardiovascular Risk. Jacobson, T.A. Mayo Clin. Proc. (2011) [Pubmed]
  3. 'Trig-onometry': non-high-density lipoprotein cholesterol as a therapeutic target in dyslipidaemia. Jacobson, T.A. Int. J. Clin. Pract. (2011) [Pubmed]
  4. A "hot" topic in dyslipidemia management--"how to beat a flush": optimizing niacin tolerability to promote long-term treatment adherence and coronary disease prevention. Jacobson, T.A. Mayo Clin. Proc. (2010) [Pubmed]
  5. Myopathy with statin-fibrate combination therapy: clinical considerations. Jacobson, T.A. Nat. Rev. Endocrinol (2009) [Pubmed]
  6. Comparison of cardiovascular event rates in patients without cardiovascular disease in whom atorvastatin or simvastatin was newly initiated. Jacobson, T.A., Wertz, D.A., Hoy, T., Kuznik, A., Grochulski, D., Cziraky, M. Mayo Clin. Proc. (2008) [Pubmed]
  7. Toward "pain-free" statin prescribing: clinical algorithm for diagnosis and management of myalgia. Jacobson, T.A. Mayo Clin. Proc. (2008) [Pubmed]
  8. Role of n-3 fatty acids in the treatment of hypertriglyceridemia and cardiovascular disease. Jacobson, T.A. Am. J. Clin. Nutr. (2008) [Pubmed]
  9. Hypertriglyceridemia and cardiovascular risk reduction. Jacobson, T.A., Miller, M., Schaefer, E.J. Clin. Ther (2007) [Pubmed]
  10. Safety considerations with gastrointestinally active lipid-lowering drugs. Jacobson, T.A., Armani, A., McKenney, J.M., Guyton, J.R. Am. J. Cardiol. (2007) [Pubmed]
  11. Beyond lipids: the role of omega-3 fatty acids from fish oil in the prevention of coronary heart disease. Jacobson, T.A. Curr. Atheroscler. Rep (2007) [Pubmed]
  12. Secondary prevention of coronary artery disease with omega-3 fatty acids. Jacobson, T.A. Am. J. Cardiol. (2006) [Pubmed]
  13. Fibrates in combination with statins in the management of dyslipidemia. Jacobson, T.A., Zimmerman, F.H. J. Clin. Hypertens. (Greenwich) (2006) [Pubmed]
  14. Statin safety: lessons from new drug applications for marketed statins. Jacobson, T.A. Am. J. Cardiol. (2006) [Pubmed]
  15. Overcoming 'ageism' bias in the treatment of hypercholesterolaemia : a review of safety issues with statins in the elderly. Jacobson, T.A. Drug. Saf (2006) [Pubmed]
  16. Effects of a global risk educational tool on primary coronary prevention: the Atherosclerosis Assessment Via Total Risk (AVIATOR) study. Jacobson, T.A., Gutkin, S.W., Harper, C.R. Curr. Med. Res. Opin (2006) [Pubmed]
  17. The safety of aggressive statin therapy: how much can low-density lipoprotein cholesterol be lowered?. Jacobson, T.A. Mayo Clin. Proc. (2006) [Pubmed]
  18. Comparative pharmacokinetic interaction profiles of pravastatin, simvastatin, and atorvastatin when coadministered with cytochrome P450 inhibitors. Jacobson, T.A. Am. J. Cardiol. (2004) [Pubmed]
  19. Combination lipid-lowering therapy with statins: safety issues in the postcerivastatin era. Jacobson, T.A. Expert. Opin. Drug. Saf (2003) [Pubmed]
  20. An assessment of obesity among African-American women in an inner city primary care clinic. Jacobson, T.A., Morton, F., Jacobson, K.L., Sharma, S., Garcia, D.C. J. Natl. Med. Assoc (2002) [Pubmed]
  21. Combination lipid-altering therapy: an emerging treatment paradigm for the 21st century. Jacobson, T.A. Curr. Atheroscler. Rep (2001) [Pubmed]
  22. "The lower the better" in hypercholesterolemia therapy: a reliable clinical guideline?. Jacobson, T.A. Ann. Intern. Med. (2000) [Pubmed]
  23. Use of a low-literacy patient education tool to enhance pneumococcal vaccination rates. A randomized controlled trial. Jacobson, T.A., Thomas, D.M., Morton, F.J., Offutt, G., Shevlin, J., Ray, S. JAMA (1999) [Pubmed]
  24. Maximizing the cost-effectiveness of lipid-lowering therapy. Jacobson, T.A., Schein, J.R., Williamson, A., Ballantyne, C.M. Arch. Intern. Med. (1998) [Pubmed]
 
WikiGenes - Universities